Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.

Standard

Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. / Effenberger, Katharina E; Johnsen, Steven A; Monroe, David G; Spelsberg, Thomas C; Westendorf, Johannes.

In: J STEROID BIOCHEM, Vol. 96, No. 5, 5, 2005, p. 387-399.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Effenberger, KE, Johnsen, SA, Monroe, DG, Spelsberg, TC & Westendorf, J 2005, 'Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.', J STEROID BIOCHEM, vol. 96, no. 5, 5, pp. 387-399. <http://www.ncbi.nlm.nih.gov/pubmed/16019205?dopt=Citation>

APA

Effenberger, K. E., Johnsen, S. A., Monroe, D. G., Spelsberg, T. C., & Westendorf, J. (2005). Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J STEROID BIOCHEM, 96(5), 387-399. [5]. http://www.ncbi.nlm.nih.gov/pubmed/16019205?dopt=Citation

Vancouver

Effenberger KE, Johnsen SA, Monroe DG, Spelsberg TC, Westendorf J. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J STEROID BIOCHEM. 2005;96(5):387-399. 5.

Bibtex

@article{4ec5f4bbbc3545f5841e094b850cfed4,
title = "Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.",
abstract = "Certain plant-derived compounds show selective estrogen receptor modulator (SERM) activity and may therefore be an alternative to the conventional hormone replacement therapy, which prevents osteoporosis but is also associated with an increased risk of breast and endometrial cancers. In the current study, we tested the effects of the hop-derived compounds 8-prenylnaringenin, 6-prenylnaringenin, xanthohumol and isoxanthohumol (1) to modulate markers of differentiation and gene expression in osteoblasts and (2) to regulate proliferation in MCF-7 breast cancer cells. Additionally, we analyzed the ER-binding affinities of these hop compounds as well as the ER-mediation of their effects. Bone-forming activity and ER-subtype specificity were investigated by measuring alkaline phosphatase (AP) activity in hFOB/ERalpha cells and regulation of gene transcription for AP, interleukin-6, pS2 and von Willebrand factor (VWF) in U-2 OS/ERalpha and U-2 OS/ERbeta cells. Our results demonstrate that AP, pS2 and VWF mRNA levels are significantly increased by the compounds in an estrogen-like manner via both ERalpha and ERbeta, while IL-6 is down-regulated in U-2 OS/ERalpha cells. Consistently, AP enzymatic activity is up-regulated by all compounds in hFOB/ERalpha9 cells. Depending on their concentration, all compounds show proliferative effects in MCF-7 cells. Except for 8-PN the hop constituents display an ERbeta-preference. Reversal of estrogen-specific AP-induction in Ishikawa cells indicates an ER-regulated mechanism. Finally, the flavonoids display cytotoxic effects only at high concentrations (> or =10(-4)M). In summary, we have demonstrated for the first time that specific phytoestrogen compounds found in hop extracts exert estrogen-like activities on bone metabolism. Regarding a potential for use in osteoporosis-prevention therapy, the dosage of a phytoestrogen, which is taken, will play an important role concerning a desired in vivo profile.",
author = "Effenberger, {Katharina E} and Johnsen, {Steven A} and Monroe, {David G} and Spelsberg, {Thomas C} and Johannes Westendorf",
year = "2005",
language = "Deutsch",
volume = "96",
pages = "387--399",
journal = "J STEROID BIOCHEM",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "5",

}

RIS

TY - JOUR

T1 - Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.

AU - Effenberger, Katharina E

AU - Johnsen, Steven A

AU - Monroe, David G

AU - Spelsberg, Thomas C

AU - Westendorf, Johannes

PY - 2005

Y1 - 2005

N2 - Certain plant-derived compounds show selective estrogen receptor modulator (SERM) activity and may therefore be an alternative to the conventional hormone replacement therapy, which prevents osteoporosis but is also associated with an increased risk of breast and endometrial cancers. In the current study, we tested the effects of the hop-derived compounds 8-prenylnaringenin, 6-prenylnaringenin, xanthohumol and isoxanthohumol (1) to modulate markers of differentiation and gene expression in osteoblasts and (2) to regulate proliferation in MCF-7 breast cancer cells. Additionally, we analyzed the ER-binding affinities of these hop compounds as well as the ER-mediation of their effects. Bone-forming activity and ER-subtype specificity were investigated by measuring alkaline phosphatase (AP) activity in hFOB/ERalpha cells and regulation of gene transcription for AP, interleukin-6, pS2 and von Willebrand factor (VWF) in U-2 OS/ERalpha and U-2 OS/ERbeta cells. Our results demonstrate that AP, pS2 and VWF mRNA levels are significantly increased by the compounds in an estrogen-like manner via both ERalpha and ERbeta, while IL-6 is down-regulated in U-2 OS/ERalpha cells. Consistently, AP enzymatic activity is up-regulated by all compounds in hFOB/ERalpha9 cells. Depending on their concentration, all compounds show proliferative effects in MCF-7 cells. Except for 8-PN the hop constituents display an ERbeta-preference. Reversal of estrogen-specific AP-induction in Ishikawa cells indicates an ER-regulated mechanism. Finally, the flavonoids display cytotoxic effects only at high concentrations (> or =10(-4)M). In summary, we have demonstrated for the first time that specific phytoestrogen compounds found in hop extracts exert estrogen-like activities on bone metabolism. Regarding a potential for use in osteoporosis-prevention therapy, the dosage of a phytoestrogen, which is taken, will play an important role concerning a desired in vivo profile.

AB - Certain plant-derived compounds show selective estrogen receptor modulator (SERM) activity and may therefore be an alternative to the conventional hormone replacement therapy, which prevents osteoporosis but is also associated with an increased risk of breast and endometrial cancers. In the current study, we tested the effects of the hop-derived compounds 8-prenylnaringenin, 6-prenylnaringenin, xanthohumol and isoxanthohumol (1) to modulate markers of differentiation and gene expression in osteoblasts and (2) to regulate proliferation in MCF-7 breast cancer cells. Additionally, we analyzed the ER-binding affinities of these hop compounds as well as the ER-mediation of their effects. Bone-forming activity and ER-subtype specificity were investigated by measuring alkaline phosphatase (AP) activity in hFOB/ERalpha cells and regulation of gene transcription for AP, interleukin-6, pS2 and von Willebrand factor (VWF) in U-2 OS/ERalpha and U-2 OS/ERbeta cells. Our results demonstrate that AP, pS2 and VWF mRNA levels are significantly increased by the compounds in an estrogen-like manner via both ERalpha and ERbeta, while IL-6 is down-regulated in U-2 OS/ERalpha cells. Consistently, AP enzymatic activity is up-regulated by all compounds in hFOB/ERalpha9 cells. Depending on their concentration, all compounds show proliferative effects in MCF-7 cells. Except for 8-PN the hop constituents display an ERbeta-preference. Reversal of estrogen-specific AP-induction in Ishikawa cells indicates an ER-regulated mechanism. Finally, the flavonoids display cytotoxic effects only at high concentrations (> or =10(-4)M). In summary, we have demonstrated for the first time that specific phytoestrogen compounds found in hop extracts exert estrogen-like activities on bone metabolism. Regarding a potential for use in osteoporosis-prevention therapy, the dosage of a phytoestrogen, which is taken, will play an important role concerning a desired in vivo profile.

M3 - SCORING: Zeitschriftenaufsatz

VL - 96

SP - 387

EP - 399

JO - J STEROID BIOCHEM

JF - J STEROID BIOCHEM

SN - 0960-0760

IS - 5

M1 - 5

ER -